N
Novavax, Inc. (NVAX)
NMS – Real vaqt narxi. Valyuta: USD
9.62
+0.12 (1.26%)
Yopilishda: May 12, 2026, 4:00 PM EDT
9.58
-0.04 (-0.42%)
Bozor oldidan: May 13, 2026, 8:22 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
9.62
+0.12 (1.26%)
Yopilishda: May 12, 2026, 4:00 PM EDT
9.58
-0.04 (-0.42%)
Bozor oldidan: May 13, 2026, 8:22 AM EDT
Novavax, Inc., biotexnologiya kompaniyasi, Qo'shma Shtatlar, Yevropa va xalqaro miqyosda jiddiy yuqumli kasalliklarning oldini olish uchun vaktsinalarni kashf qilish, ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniya COVID-19ga qarshi Nuvaxovid vaktsinasi va R21 Matrix-M adjuvant bezgak vaktsinasini tijoratlashtiradi. Kompaniya COVID-19 vaktsinasini ishlab chiqish, ishlab chiqarish va tijoratlashtirish bo'yicha Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited va Serum Life Sciences Limited bilan litsenziyalash va hamkorlik shartnomalariga ega. Kompaniya 1987-yilda tashkil etilgan bo'lib, shtab-kvartirasi Merilend shtatining Geytersberg shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Luis Sanay C.F.A. | Vice President of Investor Relations |
| Mr. Ian J. Watkins | Executive VP & Chief Human Resources Officer |
| Mr. James Patrick Kelly C.F.A. | Executive VP, CFO & Treasurer |
| Mr. John Charles Jacobs M.B.A. | President, CEO & Director |
| Mr. Mark J. Casey Esq., J.D. | Executive VP, Chief Legal Officer & Corporate Secretary |
| Mr. Richard P. Crowley | Executive VP & COO |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 8-K | nvax-20260506.htm |
| 2026-04-27 | DEFA14A | novavaxincdefa14a2026.htm |
| 2026-04-27 | DEF 14A | nvax-20260427.htm |
| 2026-02-26 | 10-K | nvax-20251231.htm |
| 2026-01-20 | 8-K | tm263587d1_8k.htm |
| 2026-01-12 | 8-K | tm262897d1_8k.htm |
| 2025-11-06 | 8-K | nvax-20251106.htm |
| 2025-11-06 | 10-Q | nvax-20250930.htm |
| 2025-11-04 | 8-K | tm2530132d1_8k.htm |
| 2025-10-22 | 8-K | tm2529188d1_8k.htm |
| Mr. Troy Morgan Esq., J.D. | Senior VP, Deputy General Counsel & Chief Compliance Officer |
| Ms. Elaine O'Hara | Executive VP & Chief Strategy Officer |
| Ms. Erika S. Trahan | Associate Director of Investor & Public Relations |
| Ms. Silvia Taylor M.B.A. | Executive VP, Chief Corporate Affairs Officer & Head of Novavax Sweden |